Present expectations in cardiac transplantation

William A Baumgartner, S. Augustine, A. M. Borkon, T. J. Gardner, B. A. Reitz

Research output: Contribution to journalArticle

Abstract

The clinical introduction of cyclosporine has resulted in increased enthusiasm for cardiac transplantation. Since July, 1983, 61 patients (50 male and 11 female) have undergone orthotopic cardiac transplantation for cardiomyopathy (48 patients), ischemic heart disease (11), or congenital heart disease (2). Mean age was 39 years (range, 1.5 to 57 years). Median hospital stay was 26 days (range, 4 to 60 days). Maintenance immunosuppression consisted primarily of prednisone and cyclosporine; it was modified in 9 patients because of a pre-existing clinical condition. The incidence of rejection was 0.44 episode/patient-month within 3 months of cardiac transplantation and 0.10 episode/patient-month subsequently. The incidence of infection was 0.05 episode/patient-month. Major side effects of cyclosporine included renal dysfunction (63%) and hypertension (61%). No recipient required dialysis for renal dysfunction. Ten patients died (rejection, 4; infection, 3; carcinoma, 1; lymphoma, 1; and pulmonary hemorrhage, 1); actuarial survival at 1 and 2 years was 84 ± 6% and 76 ± 8%, respectively. Patient follow-up (cumulative, 719 patient-months) revealed that 96% of recipients were rehabilitated and 50% had returned to work. With increasing understanding of cyclosporine immunosuppression, recipients can continue to look forward to an extended life with nearly complete rehabilitation.

Original languageEnglish (US)
Pages (from-to)585-590
Number of pages6
JournalAnnals of Thoracic Surgery
Volume43
Issue number6
StatePublished - 1987

Fingerprint

Heart Transplantation
Cyclosporine
Immunosuppression
Preexisting Condition Coverage
Incidence
Prednisone
Infection
Cardiomyopathies
Myocardial Ischemia
Renal Dialysis
Heart Diseases
Lymphoma
Length of Stay
Rehabilitation
Maintenance
Hemorrhage
Hypertension
Carcinoma
Kidney
Lung

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Baumgartner, W. A., Augustine, S., Borkon, A. M., Gardner, T. J., & Reitz, B. A. (1987). Present expectations in cardiac transplantation. Annals of Thoracic Surgery, 43(6), 585-590.

Present expectations in cardiac transplantation. / Baumgartner, William A; Augustine, S.; Borkon, A. M.; Gardner, T. J.; Reitz, B. A.

In: Annals of Thoracic Surgery, Vol. 43, No. 6, 1987, p. 585-590.

Research output: Contribution to journalArticle

Baumgartner, WA, Augustine, S, Borkon, AM, Gardner, TJ & Reitz, BA 1987, 'Present expectations in cardiac transplantation', Annals of Thoracic Surgery, vol. 43, no. 6, pp. 585-590.
Baumgartner WA, Augustine S, Borkon AM, Gardner TJ, Reitz BA. Present expectations in cardiac transplantation. Annals of Thoracic Surgery. 1987;43(6):585-590.
Baumgartner, William A ; Augustine, S. ; Borkon, A. M. ; Gardner, T. J. ; Reitz, B. A. / Present expectations in cardiac transplantation. In: Annals of Thoracic Surgery. 1987 ; Vol. 43, No. 6. pp. 585-590.
@article{711c193bdeff4422b35b22a7ebc15a3a,
title = "Present expectations in cardiac transplantation",
abstract = "The clinical introduction of cyclosporine has resulted in increased enthusiasm for cardiac transplantation. Since July, 1983, 61 patients (50 male and 11 female) have undergone orthotopic cardiac transplantation for cardiomyopathy (48 patients), ischemic heart disease (11), or congenital heart disease (2). Mean age was 39 years (range, 1.5 to 57 years). Median hospital stay was 26 days (range, 4 to 60 days). Maintenance immunosuppression consisted primarily of prednisone and cyclosporine; it was modified in 9 patients because of a pre-existing clinical condition. The incidence of rejection was 0.44 episode/patient-month within 3 months of cardiac transplantation and 0.10 episode/patient-month subsequently. The incidence of infection was 0.05 episode/patient-month. Major side effects of cyclosporine included renal dysfunction (63{\%}) and hypertension (61{\%}). No recipient required dialysis for renal dysfunction. Ten patients died (rejection, 4; infection, 3; carcinoma, 1; lymphoma, 1; and pulmonary hemorrhage, 1); actuarial survival at 1 and 2 years was 84 ± 6{\%} and 76 ± 8{\%}, respectively. Patient follow-up (cumulative, 719 patient-months) revealed that 96{\%} of recipients were rehabilitated and 50{\%} had returned to work. With increasing understanding of cyclosporine immunosuppression, recipients can continue to look forward to an extended life with nearly complete rehabilitation.",
author = "Baumgartner, {William A} and S. Augustine and Borkon, {A. M.} and Gardner, {T. J.} and Reitz, {B. A.}",
year = "1987",
language = "English (US)",
volume = "43",
pages = "585--590",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "6",

}

TY - JOUR

T1 - Present expectations in cardiac transplantation

AU - Baumgartner, William A

AU - Augustine, S.

AU - Borkon, A. M.

AU - Gardner, T. J.

AU - Reitz, B. A.

PY - 1987

Y1 - 1987

N2 - The clinical introduction of cyclosporine has resulted in increased enthusiasm for cardiac transplantation. Since July, 1983, 61 patients (50 male and 11 female) have undergone orthotopic cardiac transplantation for cardiomyopathy (48 patients), ischemic heart disease (11), or congenital heart disease (2). Mean age was 39 years (range, 1.5 to 57 years). Median hospital stay was 26 days (range, 4 to 60 days). Maintenance immunosuppression consisted primarily of prednisone and cyclosporine; it was modified in 9 patients because of a pre-existing clinical condition. The incidence of rejection was 0.44 episode/patient-month within 3 months of cardiac transplantation and 0.10 episode/patient-month subsequently. The incidence of infection was 0.05 episode/patient-month. Major side effects of cyclosporine included renal dysfunction (63%) and hypertension (61%). No recipient required dialysis for renal dysfunction. Ten patients died (rejection, 4; infection, 3; carcinoma, 1; lymphoma, 1; and pulmonary hemorrhage, 1); actuarial survival at 1 and 2 years was 84 ± 6% and 76 ± 8%, respectively. Patient follow-up (cumulative, 719 patient-months) revealed that 96% of recipients were rehabilitated and 50% had returned to work. With increasing understanding of cyclosporine immunosuppression, recipients can continue to look forward to an extended life with nearly complete rehabilitation.

AB - The clinical introduction of cyclosporine has resulted in increased enthusiasm for cardiac transplantation. Since July, 1983, 61 patients (50 male and 11 female) have undergone orthotopic cardiac transplantation for cardiomyopathy (48 patients), ischemic heart disease (11), or congenital heart disease (2). Mean age was 39 years (range, 1.5 to 57 years). Median hospital stay was 26 days (range, 4 to 60 days). Maintenance immunosuppression consisted primarily of prednisone and cyclosporine; it was modified in 9 patients because of a pre-existing clinical condition. The incidence of rejection was 0.44 episode/patient-month within 3 months of cardiac transplantation and 0.10 episode/patient-month subsequently. The incidence of infection was 0.05 episode/patient-month. Major side effects of cyclosporine included renal dysfunction (63%) and hypertension (61%). No recipient required dialysis for renal dysfunction. Ten patients died (rejection, 4; infection, 3; carcinoma, 1; lymphoma, 1; and pulmonary hemorrhage, 1); actuarial survival at 1 and 2 years was 84 ± 6% and 76 ± 8%, respectively. Patient follow-up (cumulative, 719 patient-months) revealed that 96% of recipients were rehabilitated and 50% had returned to work. With increasing understanding of cyclosporine immunosuppression, recipients can continue to look forward to an extended life with nearly complete rehabilitation.

UR - http://www.scopus.com/inward/record.url?scp=0023255810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023255810&partnerID=8YFLogxK

M3 - Article

C2 - 3296975

AN - SCOPUS:0023255810

VL - 43

SP - 585

EP - 590

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 6

ER -